Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide

The few studies that have examined rates of acute myeloid leukemia (AML) transformation in lenalidomide‐treated myelodysplastic syndrome (MDS) patients have been limited to deletion 5q MDS. The association between lenalidomide and subsequent primary malignancies (SPMs) in MDS patients has not been e...

Descripción completa

Detalles Bibliográficos
Autores principales: Rollison, Dana E., Shain, Kenneth H., Lee, Ji‐Hyun, Hampras, Shalaka S., Fulp, William, Fisher, Kate, Al Ali, Najla H., Padron, Eric, Lancet, Jeffrey, Xu, Qiang, Olesnyckyj, Martha, Kenvin, Laurie, Knight, Robert, Dalton, William, List, Alan, Komrokji, Rami S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Cancer Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944897/
https://www.ncbi.nlm.nih.gov/pubmed/27098006
http://dx.doi.org/10.1002/cam4.721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944897/
https://www.ncbi.nlm.nih.gov/pubmed/27098006
http://dx.doi.org/10.1002/cam4.721

Ejemplares similares